A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0+
SponsorTempus AI
About this trial
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
Eligibility criteria
Qualifiers
Willing and able to participate in the research and provide biospecimens
Willing and able to provide informed consent
Have documented diagnosis of AML according to the World Health Organization (WHO) classification
Secondary AML is allowed
Disqualifiers
002A: Received prior treatment for follicular lymphoma
002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN
002A: Resected patients with NED
002B: Intended for active observation
Trial design
Treatments tested in this trial
- None - Observational Study
Treatment groups
550 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov